Variant position: 265 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1023 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human KE-DKEPGEDCPSPQPAPASP RDSLALGRADP-GAPVSQEDMQ
Mouse KEEEEEVGEDCPSPWPTPASP QDSLAQDTASPDSAQPPEED
Rat KE-DEEVGEDCPSPWPAPASP QDSLGQDTANPNSAQVPKDD
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 1023 Peroxisome proliferator-activated receptor gamma coactivator 1-beta
237 – 278 Disordered
Characterization of the human, mouse and rat PGC1 beta (peroxisome-proliferator-activated receptor-gamma co-activator 1 beta) gene in vitro and in vivo.
Meirhaeghe A.; Crowley V.; Lenaghan C.; Lelliott C.; Green K.; Stewart A.; Hart K.; Schinner S.; Sethi J.K.; Yeo G.; Brand M.D.; Cortright R.N.; O'Rahilly S.; Montague C.; Vidal-Puig A.J.;
Biochem. J. 373:155-165(2003)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4); TISSUE SPECIFICITY; FUNCTION; VARIANT GLN-265;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.